Immix Biopharma

Immix Biopharma is a clinical-stage biopharma developing personalized therapies for oncology and immunology. Lead asset NXC-201 is a BCMA-targeting CAR-T asset, being evaluated for amyloid light chain amyloidosis and multiple myeloma, with plans to expand to autoimmune indications.

Equities

Equities by Sector

Sectors

Thematics

Latest

The plan to deliver $4–5bn in cost savings is central to bp’s renewed strategy. Is it realistic?

Deep dive into bp’s case for income investment

The bull case deep dive: A closer look at bp’s cash flows

Audiovisual

Latest

Edinburgh Worldwide Investment Trust in 60 seconds

Under-Owned, Undervalued, Unapologetic: Nick Train’s Case for UK Equities

Starpharma – executive interview

About Edison

About Edison

Careers

Immix Biopharma (NASDAQ: IMMX)

Latest News

Latest Insights

Immix Biopharma — Promising NEXICART-2 data; runway extended

Immix Biopharma — Primed to pick up the pace in ALA

Immix (NASDAQ: IMMX) to present NEXICART-2 update at ASH 2025

Immix Biopharma — NEXICART-2 enrolment progressing well

Sector

Equity Analyst

Key Management

Research

Immix Biopharma — NXC-201 receives FDA RMAT designation

Immix Biopharma — Shifting the ALA treatment paradigm with CAR-T

Immix Biopharma — All eyes on NEXICART-2

Immix Biopharma — US CAR-T trial progresses to dose expansion

Immix Biopharma — Full steam ahead with US CAR-T trial

Immix Biopharma — US$8m grant to advance novel CAR-T treatment

Immix Biopharma — US CAR-T trial commences patient dosing

Immix Biopharma — All roads lead to NEXICART-2

Immix Biopharma — Reaffirmed long-term focus on outpatient CAR-T

Immix Biopharma — Marching towards US clinical trials for NXC-201

Immix Biopharma — 2023 recap with a preview of active year ahead

Immix Biopharma — Updates galore: NXC-201 ODD (EU) and raise

Immix Biopharma — Increased legroom following common-only raise

Immix Biopharma — Encouraging stream of ALA data newsflow

Immix Biopharma — KOL event: Glimmer of hope for ALA patients

Immix Biopharma — CAR-T trial moves to US with outpatient potential

Immix Biopharma — A quarter of progress for both lead assets

Immix Biopharma — A step toward delivering a practical CAR-T option

Immix Biopharma — NXC-201 gains orphan drug designation in ALA

Immix Biopharma — NXC-201 gains Orphan Drug designation in MM

Immix Biopharma — Progressing as expected on all fronts

Immix Biopharma — IMX-110 interim results in colorectal cancer

Immix Biopharma — ATM completion may extend runway into H224

Immix Biopharma — A quarter focusing on a CAR-T strategy

Immix Biopharma — CAR-T treatment continues to show promise

Immix Biopharma — Pipeline momentum continues in FY23

Immix Biopharma — Positive data from CAR-T treatment continues

Immix Biopharma — Expanding portfolio into CAR-T cell therapy

Immix Biopharma — Encouraging progress on multiple fronts

Immix Biopharma — Potential upside with expansion into CAR-T

Immix Biopharma — IMX-110 clinical expansion on the horizon

Immix Biopharma – executive interview

Immix Biopharma — Fresh faces with a unique tissue-targeting therapy